Condition: Neuroendocrine Tumor · Neuroblastoma · Pheochromocytoma · Sponsor: Peking Union Medical College Hospital
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroendocrine tumors mainly in pheochromocytoma and paraganglioma (PPGL) and neuroblastoma (NB).
This description comes directly from the study's public registry record.
Peipei Wang · 18511395988 · wpp199411@163.com
Always discuss trial participation with your own doctor first.
| Peking union medical college hospital | Beijing, Dongcheng, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05069220